Pelthos Therapeutics Inc.
PTHS
$23.42
-$1.13-4.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 650.60% | 658.65% | 342.18% | 466.95% | 478.64% |
| Gross Profit | 2,422.78% | 2,395.48% | 1,081.60% | 748.34% | -478.64% |
| SG&A Expenses | 1,033.94% | 843.27% | 564.21% | 296.50% | 24.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,014.12% | 855.48% | 550.17% | 208.10% | 0.78% |
| Operating Income | -529.63% | -484.71% | -328.34% | -131.16% | -0.78% |
| Income Before Tax | -937.61% | -902.79% | -537.42% | -138.83% | 7.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -855.88% | -802.43% | -444.56% | -134.21% | 7.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -855.88% | -802.43% | -444.56% | -134.21% | 7.73% |
| EBIT | -529.63% | -484.71% | -328.34% | -131.16% | -0.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -80.29% | -101.92% | -41.14% | 46.15% | 66.06% |
| Normalized Basic EPS | -92.82% | -120.12% | -56.54% | 45.67% | 66.06% |
| EPS Diluted | -80.29% | -101.92% | -41.14% | 46.15% | 66.06% |
| Normalized Diluted EPS | -92.82% | -120.12% | -56.54% | 45.67% | 66.06% |
| Average Basic Shares Outstanding | 433.91% | 328.99% | 235.55% | 169.90% | 81.86% |
| Average Diluted Shares Outstanding | 433.91% | 328.99% | 235.55% | 169.90% | 81.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |